Floatz logo

FLUOROURACILUM

KRAS Wildtype

PD Dr. med. Volker HeinemannSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the KRAS Wildtype cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
University Health Network, Toronto
Phase 2B
gsk1120212
University Health Network, Toronto
Phase 2B
Folic Acid
PD Dr. med. Volker Heinemann
Phase 2CCC
Eloxatin
PD Dr. med. Volker Heinemann
Phase 2CCC

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →